Lyell Immunopharma (LYEL) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 43.0% versus a loss of 50.8%. Over five years, LYEL leads with a -97.1% price change compared with -97.3% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($209.0 million vs $199.0 million), about 1.1 times the size, while Lyell Immunopharma is growing revenue faster (-41.0% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYEL | ZNTL |
|---|---|---|
| Share price | $8.12 | $2.13 |
| Market cap | $198.98M | $209.00M |
| 1-day change | -0.85% | -4.91% |
| YTD return | -73.62% | +57.78% |
| 1-year return | -50.79% | +42.95% |
| 5-year return | -97.06% | -97.27% |
| EPS (TTM) | $-12.86 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.00K | $0 |
| Revenue growth (YoY) | -40.98% | -100.00% |
| Net income (latest FY) | $-274.45M | $-137.06M |
| Operating margin | -748344.44% | — |
| Net margin | -762355.56% | — |
| 52-week high | $45.00 | $6.95 |
| 52-week low | $7.20 | $1.21 |
| Distance from 52-week high | -81.96% | -69.35% |
| Analyst consensus | none | buy |
| Avg. price target upside | +366.50% | +249.30% |
| Average volume | 152.61K | 1.17M |
| Shares outstanding | 24.51M | 98.12M |
| Employees | 161 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed LYEL by 93.7 percentage points over the past year.
- Lyell Immunopharma grew revenue faster in its latest fiscal year (-40.98% vs -100.00%).
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
LYEL vs ZNTL FAQ
Which is bigger, Lyell Immunopharma or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $209.00M compared with $198.98M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, LYEL or ZNTL?
ZNTL returned +42.95% over the past 12 months, compared with -50.79% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Lyell Immunopharma and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.